Literature DB >> 6211138

Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam into bone.

J T Summersgill, L G Schupp, M J Raff.   

Abstract

The concentrations of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam in the serum, femurs, and scapulae of normal rats were measured microbiologically 0.5, 1, 1, and 4 h after intravenous injection of 15-, 15-, 20-, 40-, 75-, and 30-mg/kg doses of the respective drugs. By 0.5 h metronidazole reached levels of 3.0 micrograms/g in compact femoral bone and 2.7 micrograms/g in cancellous scapular bone. Clindamycin and chloramphenicol reached levels of 8.1 and 6.1 micrograms/g, respectively, at 0.5 h. Cefoxitin penetrated bone to a level of 2.6 micrograms/g, whereas ticarcillin and moxalactam failed to reach significant levels in bone after single intravenous doses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6211138      PMCID: PMC181949          DOI: 10.1128/AAC.21.4.601

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Bioassay of metronidazole with either anaerobic or aerobic incubation.

Authors:  E D Ralph; W M Kirby
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

2.  Bone infections involving anaerobic bacteria.

Authors:  R P Lewis; V L Sutter; S M Finegold
Journal:  Medicine (Baltimore)       Date:  1978-07       Impact factor: 1.889

3.  Treatment with metronidazole of 48 patients with serious anaerobic infections.

Authors:  H Giamarellou; K Kanellakopoulou; D Pragastis; N Tagaris; G K Daikos
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Intravenous metronidazole in the treatment and prophylaxis of anaerobic infection.

Authors:  M Perera; P M Chipping; P Noone
Journal:  J Antimicrob Chemother       Date:  1980-01       Impact factor: 5.790

6.  Anaerobic osteomyelitis.

Authors:  M J Raff; J C Melo
Journal:  Medicine (Baltimore)       Date:  1978-01       Impact factor: 1.889

7.  Chloramphenicol bioassay.

Authors:  R M Bannatyne; R Cheung
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

8.  Metronidazole treatment of Bacteroides fragilis infections.

Authors:  J C Melo; M J Raff; H F Wunderlich; C H Chun; J T Summersgill; R Varghese
Journal:  Am J Med Sci       Date:  1980 Nov-Dec       Impact factor: 2.378

Review 9.  Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

10.  Susceptibilities of anaerobic bacteria to cefoperazone and other antibiotics.

Authors:  D Kaye; W Kobasa; K Kaye
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

View more
  15 in total

1.  Unusual findings and diagnostic challenges in a child with Lemierre's disease.

Authors:  Florian Gahleitner; Abid M Hussain; Julian Gaskin; Andrew A Moir; Nelun Perera; James Greening
Journal:  BMJ Case Rep       Date:  2009-08-11

2.  Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.

Authors:  Emmanuel Curis; Vincent Pestre; Vincent Jullien; Luc Eyrolle; Denis Archambeau; Philippe Morand; Laure Gatin; Matthieu Karoubi; Nicolas Pinar; Valérie Dumaine; Jean-Claude Nguyen Van; Antoine Babinet; Philippe Anract; Dominique Salmon
Journal:  Infection       Date:  2015-04-03       Impact factor: 3.553

3.  Haematogenous clavicular osteomyelitis caused by Bacteroides fragilis.

Authors:  A E Studemeister; B J Dreyfuss
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

4.  The management gram-negative bacterial haematogenous vertebral osteomyelitis: a case series of diagnosis, treatment and therapeutic outcomes.

Authors:  Simon Matthew Graham; Adelle Fishlock; Peter Millner; Jonathan Sandoe
Journal:  Eur Spine J       Date:  2013-04-01       Impact factor: 3.134

Review 5.  Prevention and management of prosthetic joint infection in older adults.

Authors:  Emily K Shuman; Preeti N Malani
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

6.  Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams; L Morrison
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 7.  Bone and joint infections due to anaerobic bacteria: an analysis of 61 cases and review of the literature.

Authors:  G Walter; M Vernier; P O Pinelli; M Million; M Coulange; P Seng; A Stein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-28       Impact factor: 3.267

8.  Continuous clindamycin infusion, an innovative approach to treating bone and joint infections.

Authors:  Valérie Zeller; Arnaud Dzeing-Ella; Marie-Dominique Kitzis; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

9.  Azlocillin and cefonicid penetration into bone enhanced by probenecid.

Authors:  J T Summersgill; L G Harrod; M J Raff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

10.  Efficacy and safety of clindamycin-based treatment for bone and joint infections: a cohort study.

Authors:  J Courjon; E Demonchy; E Cua; E Bernard; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.